Shares of Reckitt Benckiser Group Plc (LON:RB) have been given a consensus recommendation of “Hold” by the twenty-one analysts that are presently covering the company, MarketBeat reports. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is GBX 6,806 ($88.93).

A number of research analysts recently issued reports on the company. Royal Bank of Canada set a GBX 5,100 ($66.64) price target on Reckitt Benckiser Group and gave the stock a “sell” rating in a research note on Monday, December 31st. JPMorgan Chase & Co. set a GBX 9,000 ($117.60) target price on Reckitt Benckiser Group and gave the company a “buy” rating in a research note on Monday. Goldman Sachs Group lifted their target price on Reckitt Benckiser Group from GBX 7,025 ($91.79) to GBX 7,090 ($92.64) and gave the company a “neutral” rating in a research note on Tuesday, October 30th. Credit Suisse Group lifted their target price on Reckitt Benckiser Group from GBX 5,850 ($76.44) to GBX 5,950 ($77.75) and gave the company an “underperform” rating in a research note on Wednesday, October 31st. Finally, Berenberg Bank lifted their target price on Reckitt Benckiser Group from GBX 7,300 ($95.39) to GBX 7,450 ($97.35) and gave the company a “buy” rating in a research note on Thursday, November 8th.

LON:RB traded up GBX 80 ($1.05) during mid-day trading on Friday, reaching GBX 6,177 ($80.71). 1,178,083 shares of the stock were exchanged, compared to its average volume of 1,720,000. Reckitt Benckiser Group has a 1 year low of GBX 5,562 ($72.68) and a 1 year high of GBX 8,110.43 ($105.98).

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.

Read More: What is the downside to momentum investing?

Analyst Recommendations for Reckitt Benckiser Group (LON:RB)

Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.